MMP2 Protein (His tag)

Catalog No. ABIN7669278

Recombinant MMP2 protein expressed in Escherichia coli (E. coli).

Quick Overview for MMP2 Protein (His tag) (ABIN7669278)

Target: MMP2 (Matrix Metalloproteinase 2 (MMP2))

Protein Type: Recombinant

Biological Activity: Inactive

Origin: Human

Source: Escherichia coli (E. coli)

Purity: > 95 %

Product Details

Purification tag / Conjugate: This MMP2 protein is labelled with His tag.

Purpose: Recombinant Human MMP2 protein(N-His)

Sequence: Tyr 110-Cys 660

Sterility: 0.2 μm filtered

Endotoxin Level: < 0.1 EU per μg of the protein as determined by the LAL method.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 8.0.
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween 80 are added as protectants before lyophilization.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Expiry Date: 12 months

Target Details

Target: MMP2 (Matrix Metalloproteinase 2 (MMP2))

Alternative Name: MMP2

Background: Matrix Metalloproteinase-2 (MMP-2) is an enzyme that degrades components of the extracellular matrix and thus plays a pivotal role in cell migration during physiological and pathological processes. MMP-2 expression is dependent on extracellular matrix metalloproteinase inducer (EMMPRIN), Her2/neu, growth factors, cytokines, and hormones. Pro-MMP-2 activation needs MT1-MMP and TIMP-2 contribution. MMP-2 is changed in distribution and increased in amount in the ventral cochlear nucleus after unilateral cochlear ablation. A low level of MMP-2 is linked to favorable prognosis in patients with a hormone receptor-negative tumor, usually associated with high risk. As a zymogen requiring proteolytic activation for catalytic activity, MMP-2 has been implicated broadly in the invasion and metastasis of many cancer model systems, including human breast cancer (HBC). Blocking MMP-2 secretion and activation during breast carcinoma development may decrease metastasis. The detection of active MMP-2 alone or the rate of pro-MMP-2 and active MMP-2 is considered a very sensitive indicator of cancer metastasis. Modulation of MMP-2 expression and activation through specific inhibitors and activators may thus provide a new mechanism for breast cancer treatment.,Gelatinase A,TBE-1

Molecular Weight:

calculated_mw: 63.0 kDa

observed_mw: 66 kDa

UniProt: P08253

Pathways: Activation of Innate immune Response